Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVUS-ACS and ULTIMATE-DAPT Trials in Acute Coronary Syndrome
NCT03971500Active, not recruiting
- Sponsor
- Nanjing First Hospital
- Start
- Aug 2019
- Primary completion
- Oct 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, double-blind trial of ticagrelor and aspirin in acute coronary syndrome (ACS) (4 arms), sponsored by Nanjing First Hospital. Primary endpoints: Target vessel failure at 12 months, Clinically-relevant bleeding at 11 months and 1 more. Started Aug 2019; status: active, not recruiting.
02
Drugs
ticagreloraspirin
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT03971500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03971500.